Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends shaping patient access in 2025.
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
The latest update is out from Alvotech ( (ALVO) ).
AbbVie ABBV has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic areas. The company’s pipeline spans immunology therapies, expanding oncology ...
Based on the forward 12-month price-to-earnings (P/E F12M), a commonly used multiple for valuing generic companies, the industry is currently trading at 14.37X compared with the S&P 500’s 23.61X and ...
Johnson & Johnson JNJ and AbbVie ABBV are both pharma-driven healthcare giants with a strong presence in immunology, oncology and neuroscience areas. Other than that, J&J also has drugs for ...
Specialty drug spending rose 9.6% in 2024, but Humira biosimilar adoption is helping to slow cost increases. The switch to the biosimilars of Humira (adalimumab) is beginning to slow the cost per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback